type here...

Latest news

Commercial

AstraZeneca’s Alexion Signs $825 Million Gene Therapy Licensing Deal with JCR Pharmaceuticals

AstraZeneca’s rare disease division, Alexion, has finalized a license agreement with JCR Pharmaceuticals valued at up to $825 million....
Newsletter

Life Sciences Voice Top Five Newsletter

Welcome to this week’s edition of the Life Sciences Voice Top Five Newsletter, your go-to source for the latest...
Clinical

4DMT Accelerates Phase 3 Eye Gene Therapy Trials Despite 25% Workforce Reduction

4D Molecular Therapeutics (4DMT) is pressing ahead with its late-stage gene therapy ambitions even as it undergoes significant internal...
Regulatory

FDA Grants Accelerated Approval to Regeneron’s Lynozyfic for Advanced Multiple Myeloma

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Regeneron’s bispecific antibody linvoseltamab, now branded as...
Clinical

Bezuclastinib Meets Primary Endpoint in Phase 3 Trial for Systemic Mastocytosis

Cogent Biosciences has announced that its Phase 3 trial...
Clinical

Cosentyx Misses Primary Endpoint in Phase III Giant Cell Arteritis Trial

Novartis has reported that its anti-inflammatory drug Cosentyx did...
Manufacturing

Sandoz Begins Construction on $440M Biosimilar Facility in Slovenia as Part of $1.1B Investment Drive

Sandoz has broken ground on a new $440 million biosimilar manufacturing facility in Brnik, Slovenia, as part of a...
Clinical

Organon Says Goodbye to Endometriosis Drug Candidate After Phase 2 Failure

An Organon medication candidate, regarded as its most significant prospective chance, has failed a phase 2 study, leading the...
Commercial

Shionogi Acquires Rights to BioVersys’ BV500 Program Targeting NTM Infections

Shionogi & Co. has entered into a new agreement with Swiss biotech BioVersys to acquire rights to its preclinical...
Clinical

Atai–Beckley Merger Moves Forward After Psychedelic Nasal Spray Shows Promise in Depression Trial

Following promising Phase 2b results, Atai Life Sciences has...
Commercial

Argenx and Unnatural Products Sign $1.5 Billion Deal to Develop Macrocyclic Peptide Therapies

Argenx has entered into an agreement with California-based Unnatural...
Commercial

BerGenBio and Oncoinvent to Merge Amidst Former’s Cancer Drug Failure

BerGenBio, impacted by the unsuccessful outcome of its primary oncology medication, has chosen to merge with the Norwegian biotechnology...
Commercial

Xoma Acquires Turnstone Biologics in $8M Deal Amid Industry Struggles

Xoma Royalty acquires struggling San Diego biotech Turnstone Biologics for $7.9M after halted trials and layoffs. Explore the details...
Manufacturing

Sage Therapeutics to Lay Off All 338 Employees Following Supernus Acquisition

Sage Therapeutics will lay off all 338 employees following its $561M acquisition by Supernus. Discover how the deal, centered...
WhatsApp Image 2025 05 31 at 23.49.00 cd2174e0 min
Commercial

AstraZeneca’s Alexion Signs $825 Million Gene Therapy Licensing Deal with JCR Pharmaceuticals

AstraZeneca’s rare disease division, Alexion, has finalized a license...
Editorial Team -
Commercial

AmerisourceBergen Sheds Its Decades-Old Identity to Emerge as Cencora

AmerisourceBergen, the pharmaceutical manufacturing and services firm, has retired...
Commercial

Roche to lay off 300 to 400 employees in product development jobs

Roche’s executives, including CMO (Chief Medical Officer) Levi Garraway, claimed in a recorded video conference with staff acquired by Swiss Newspaper Blick

Popular

Most popular life news you must read today

View all articles

Commercial

Information Technology

Chugai and Gero Partner to Develop Antibodies for Age-Related Diseases Using AI

Chugai Pharmaceutical has entered into a research collaboration with Singapore-based Gero to develop antibody-based...
Editorial Team -

J&J MedTech presents the first Ottava surgical robot clinical cases

Johnson & Johnson MedTech successfully conducted the initial clinical use of Ottava surgical robot...
Editorial Team -

Wisp Launches Weight Care Vertical for Women with Hormonal Imbalances

Common conditions in women such as PCOS, menopause, and endometriosis often lead to hormonal...
Editorial Team -

PicnicHealth Launches New Service Bringing Observational Clinical Trials to the Virtual Realm

Health technology company PicnicHealth has launched a new product, Virtual Site, which allows researchers...
Editorial Team -

Regulatory

Newsletter

Life Sciences Voice Top Five Newsletter

Welcome to this week’s edition of the Life Sciences...
Clinical

4DMT Accelerates Phase 3 Eye Gene Therapy Trials Despite 25% Workforce Reduction

4D Molecular Therapeutics (4DMT) is pressing ahead with its...
Regulatory

FDA Grants Accelerated Approval to Regeneron’s Lynozyfic for Advanced Multiple Myeloma

The U.S. Food and Drug Administration (FDA) has granted...
Technology

Chugai and Gero Partner to Develop Antibodies for Age-Related Diseases Using AI

Chugai Pharmaceutical has entered into a research collaboration with...

Research & Development

Market Access

Manufacturing

French Company Orano Med Opens New Radiation Production Facility Near Indianapolis

In a nuclear medicine surge, industry leader Orano Med...
Manufacturing

Gerresheimer Increases the Capabilities of Medical Systems in the USA

Gerresheimer, the maker of innovative systems and solutions and...

Manufacturing & RegulatoryPOPULAR
Find Your Perfect Music Festival

Commercial

AstraZeneca’s Alexion Signs $825 Million Gene Therapy Licensing Deal with JCR Pharmaceuticals

AstraZeneca’s rare disease division, Alexion, has finalized a license...
Editorial Team -
Clinical

4DMT Accelerates Phase 3 Eye Gene Therapy Trials Despite 25% Workforce Reduction

4D Molecular Therapeutics (4DMT) is pressing ahead with its...
Editorial Team -

Editor Picks

Must Read

Hot Topics

About Us

Life Sciences Voice is the leading resource for life sciences executives to get crucial insights, explore the latest innovations, and learn about industry trends. Life Sciences Voice provides the community with thought-provoking commentary in multiple formats covering a range of issues from drug discovery to commercial success.

Contact us: reachout(at)lifescivoice.com

Follow Us

© Copyright - Life Sciences Voice